Pilot study shows imaging diagnostic to be well tolerated
May 2014
by  |  Email the author


CAMBRIDGE, Mass.—Merrimack Pharmaceuticals Inc. has announced Phase 1 results from its clinical pilot study of ferumoxytol, an iron oxide nanoparticle. The study demonstrated that the compound was well tolerated when used as a tumor contrast agent prior to treatment with MM-398, which is being evaluated as a treatment for both metastatic pancreatic cancer and metastatic colorectal cancer.
“This application of ferumoxytol magnetic resonance imaging has the potential to become a minimally invasive predictive biomarker for liposomal therapies. We hope that the continuation and expansion of this approach will allow us to identify patients most likely to benefit from MM-398 treatment … we are encouraged to see that almost all of the tumor lesions that shrank after MM-398 treatment were associated with higher levels of ferumoxytol, as seen on the MRI,” said Dr. Jonathan Fitzgerald, Merrimack’s senior director of discovery.

Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.